Last reviewed · How we verify

NCT00662077

Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort

Withdrawn Phase 4 Last updated 13 March 2019
What this trial tests

Phase 4 trial testing Ibandronate in HIV Infections. Withdrawn.

Quick facts

Lead sponsorGermans Trias i Pujol Hospital
PhasePhase 4
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Germans Trias i Pujol Hospital

Who can join

18 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project wills to determine the incidence of osteoporosis in our population of HIV-infected patients and to assess the efficacy and security of ibandronate, whose efficacy in post-menopausal women has already been proved.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ibandronate

Trials testing the same drug.

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

Other Germans Trias i Pujol Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00662077.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing